

LoopLab

LOOP LAB

Transforming Immunotherapy Through Targeted Immune Tolerance



INNOVATION WITH GLOBAL IMPACT

Novel platform and transformative approach addresses current challenges in treating autoimmune and immune-related diseases



PROPRIETARY TECHNOLOGY (ROBUST IP)

Proprietary, modular, first-in-class Fc-Engager technology is designed to induce antigen-specific immune tolerance in disease-causing cells with increased potency and durability



EXPERIENCED & SUCCESSFUL TEAM

Experienced team of biotech veterans and scientific experts will rapidly demonstrate proof-of-concept with a clear path to first-in-human studies



EXPANSIVE MARKET POTENTIAL

Modular platform design enables scalability for new disease targets to feed LoopLab's own pipeline and that of potential partners




INDEPENDENTLY FUNDED THROUGH 2027

Seed funding in place to reach multiple value inflection points in the next 12-18 months

Unmet Clinical Needs in High-Value Immune Therapies

- Gaps in current therapy due to lack of specificity
- Opportunity for new therapy (200B)



Unpredictable Disease Progression
Current therapies imprecisely target the immunological trigger(s) due to patient heterogeneity



Broad Immunosuppression
Existing drugs suppress the entire immune system leading to infections, cancer risk, and poor quality of life



Lack of Durability
Patients require lifelong treatment with high costs and relapses are common



Broad Range of High-Need Indications
Autoimmune: bullous pemphigoid (skin), T1D (metabolic), celiac (GI)
Immune-Related: anti-drug antibody management, transplant, blood disorders, allergies




Massive Market Opportunity (200B)
Combined market exceeds \$200Billion




Growing Deal & Partnership Momentum
Multiple M&A and licensing deals in tolerance inducing therapy

The "Swiss Army Knife" to Immune Tolerance

1. ENGAGING INHIBITORY (Fc)-RECEPTORS ON IMMUNE CELLS
2. CROSSLINKS INHIBITORY Fc-RECEPTORS TO B-CELL RECEPTORS
3. UNLOCKS TOLERANCE INDUCTION ON DISEASED CELLS



Achieving Comprehensive Immune Tolerance via B-Cells, Dendritic Cells, and Liver Cells



B-Cells

- Crosslinks inhibitory Fc-receptors to BCRs
- Reduces B-cell activation
- Minimizes autoantibody production



Dendritic Cells


- Crosslinks Immune complexes to DCs
- Drives DCs towards tolerogenic phenotype
- Lowers T-cell-driven inflammation
- Encourages regulatory T-cell expansion




Liver Cells (LSECs)

- Captures autoantibodies
- Shuttles captured Abs to the liver
- Reinforces systemic immune tolerance
- Contributes to removal of immune complexes

TOLEROGENIC FC-ENGAGERS DEMONSTRATE INHIBITORY FUNCTIONALITY IN VITRO



ANTIGEN-SPECIFIC PREVENTION OF B-CELL RESPONSE IN VIVO




Fc Engager's Innovative Mechanism uniquely harnesses inhibitory Fc receptors to reprogram immune tolerance.

Data Highlights:

- Significant reduction in mast cell degranulation
- Suppression of antigen-specific antibody production in human-relevant models
- Specific binding to inhibitory Fc-receptors

High-Specificity Tolerance Induction: LoopLab's Differentiated Fc Engineering


High Specificity / Tolerance Induction



A First-in-Class Therapeutic Platform for Autoimmune Diseases



LoopLab's Strategic and Focused Development Plan to FiH



WE INVITE STRATEGIC DIALOGUE AND CO-DEVELOPMENT POSSIBILITIES BEFORE FORMAL FUNDING ROUNDS BEGIN

Experiences and successful leadership



Jochen Stritzker, PhD

- CSO, interim CEO
- 20+ years in Biotech & Pharma (Europe and US)
- Previous companies: Genelix (IPO), Themis (acquired), Merck (US)
- Numerous publications & patents



Simona Neubauer, Mag., MBA

- COO
- 15+ years in Pharma & Biotech
- Previous companies: Baxter, Alcon, Kwizda Pharmadistribution
- Various roles in Quality Assurance



Eva Mihailovska, PhD

- CDO
- 15+ years in biomedical research
- Previous companies: Evotec, Valneva, Affiris AG
- PhD in molecular biology



Andrea Vogel, PhD

- Head of Research
- Academic track record
- PhD in immunology
- Numerous publications

Board

- Liz Leveille
- Oscar Izeboud
- Bernd Jilma

- VP Boston & European Innovation Hubs, MSD
- CEO, Scenic Biotech
- Prof. Dr., Medical University Vienna

Scientific Advisory Board

- Falk Nimmerjahn
- Bart Lambrecht
- Friedrich Scheiflinger
- Enno Schmid
- Gordana Wozniak-Knopp

- Prof., Univ. Erlangen-Nürnberg (Fc-receptor expert)
- Prof., Univ. Ghent (Fc-receptor & allergy expert)
- FS Pharma Consulting GmbH & Senior Biotech & Pharma Executive
- Prof., Univ. Lübeck (expert on autoimmune disease of the skin)
- Prof., BOKU Vienna (antibody engineering expert, Co-founder of Fstar)

Collaborators

- Gordana Wozniak-Knopp
- Peter Steinberger
- Klaus Schmetterer
- Gernot Schabbauer

- Prof., BOKU Vienna (Yeast library screen (FFG-funded project))
- Prof., Medical University Vienna (functional assay and reporter cell projects)
- Prof., Medical University Vienna (immune organoid project)
- Prof., Medical University Vienna (in vivo studies)

MAJOR OUT-LICENSING POTENTIAL



CELIAC DISEASE



ALLERGIES



ANTI-DRUG ANTIBODIES



BULLOUS PEMPHIGOID



[http://](http://www.looplab.bio)

[WWW.LOOLAB.BIO](http://www.looplab.bio)

CONTACT:
SIMONA NEUBAUER COO
PHONE +43 12367151
MOBILE +43 676 8434 96 771
SIMONA.NEUBAUER@LOOLAB.BIO